Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of New Finerenone High-Strength Tablet
NCT07116512Phase 1Completed
- Sponsor
- Bayer
- Start
- May 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of finerenone in heart failure (HF) (2 arms), sponsored by Bayer. Primary endpoints: Maximum observed drug concentration in plasma and Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration. Started May 2023; status: completed.
02
Drugs
finerenone
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT07116512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07116512.